Post-earnings recap
Reported
Mon, May 11, 2026
EPS actual
$1.60
EPS est.
$1.46
EPS surprise
+9.74%
1-day move
+3.57%
Halozyme Therapeutics reported a strong earnings per share, exceeding expectations by nearly 10%. However, revenue figures were not disclosed, leaving some uncertainty. The stock reacted positively, increasing by 3.57%, likely driven by the better-than-expected EPS performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.60 | $1.52 | +9.74% |
| Revenue | — | $359M | — |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Halozyme is known for its proprietary enzyme technology that enhances the delivery of biologic drugs, which is increasingly important as the demand for effective treatments grows.
Last quarter
In Q4-2025, Halozyme reported an EPS of -$0.24, significantly missing analyst expectations of $2.06. This disappointing performance led to a modest stock increase of 1.31% the following day.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+6.80%
Avg 1-day reaction
+0.95%
Analysts are cautiously optimistic about Halozyme's upcoming earnings, expecting an EPS of $1.52 and revenue of $359 million. The company has a strong track record of beating EPS estimates, which could lead to positive market reactions.
Bull case
If Halozyme meets or exceeds EPS expectations, it could signal strong operational performance and boost investor confidence, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company misses earnings expectations again, it may raise concerns about its financial health and management effectiveness, leading to a negative reaction in the stock price.
Key metrics to watch
EPS
$1.52Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue
$359MRevenue figures will provide insights into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Halozyme achieve an EPS of at least $1.52?
This figure is critical as it reflects the company's ability to generate profit and meet market expectations, which could significantly influence stock performance.
Q2
What are the revenue figures compared to the expected $359 million?
Revenue performance will indicate market demand for Halozyme's products and its overall financial health, impacting investor sentiment.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±4.6%
Why consensus could be wrong
The Street may be underestimating the potential for Halozyme to exceed its EPS expectations due to its strong history of beating estimates, despite recent setbacks.
Supporting evidence
Halozyme has an 88% EPS beat rate in recent quarters, indicating a strong likelihood of positive surprises.
The stock has shown resilience with modest increases following earnings misses, suggesting underlying strength.
Options are pricing a 5.2% move, which is higher than the historical average, indicating that the market may be overly cautious.
Key risk
If Halozyme's revenue exceeds $378 million, it could significantly alter the market's perception of its growth potential.
Pre-commit to what would confirm each case.
The market is closely watching these earnings figures as they will determine the company's financial trajectory and investor sentiment.
Bull confirmed if
Achieving an EPS of $1.52 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $1.42 would raise serious concerns about the company's profitability and growth prospects.
What the market is pricing for the move.
Implied Move
±5.2%
Historical Avg
±1.6%
The options market is pricing in a potential move of about 5.2% in either direction following the earnings report, indicating heightened uncertainty among investors.
Options are pricing ±5.6% while HALO has averaged ±1.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
27.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 6 of 12 (50%)
This setup has occurred 30 times across Health Care in the last 2 years. 6 of 12 faded and 6 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.5%, with a raw directional average of -0.4% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$567,660.74
5,230 sh
1 insider
Net
$567,660.74
Net selling
Most Active Insiders· 4 open-market trades
Smart-money positioning from the most recent 13F filings.
Institutional
113.09%
of float
Insider
1.09%
of float
Holders
909
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,271,095 sh · $1.5B
11.69%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Halozyme beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further commentary from management.
Miss
Should the company miss earnings expectations, history suggests a potential decline of around 1.31% on the first day, raising concerns about its financial health.
The lines on the call that would change the story.
$567,660.74
Net selling
Recent Transactions
Oct 1, 2026 · @ $108.45
3,300 sh
$357,898.20
Oct 1, 2026 · @ $109.57
1,100 sh
$120,525.90
Oct 1, 2026 · @ $107.17
730 sh
$78,232.64
Oct 1, 2026 · @ $110.04
100 sh
$11,004.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Capital Management LLC
5,351,312 sh · $592.9M
4.71%
1.5%
Vanguard Portfolio Management LLC
5,299,008 sh · $587.1M
4.67%
0.9%
State Street Corporation
5,179,434 sh · $573.8M
4.56%
4.9%
Invesco Ltd.
3,177,997 sh · $352.1M
2.80%
-20.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.